Brief: HLS Therapeutics announces Health Canada approval of NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease
18/11/2025 12:14
Nov 18 (Reuters) - HLS Therapeutics Inc HLS.TO : HLS THERAPEUTICS ANNOUNCES HEALTH CANADA APPROVAL OF NILEMDO® FOR THE REDUCTION OF LDL-CHOLESTEROL IN CANADIANS AT RISK OF CARDIOVASCULAR DISEASE HLS THERAPEUTICS INC - COMMERCIAL LAUNCH EXPECTED IN Q2 2026 Source text: nCNWJ9L6Xa Further company coverage: HLS.TO ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Esperion Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
U.S. RESEARCH ROUNDUP- Applied Materials, Axsome Therapeutics, Onsemi